GALDERMA
Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 2024 and beyond. This project is the culmination of a year of comprehensive trend-forecasting research, conducted in collaboration with a network of renowned experts.
Aesthetics is increasingly becoming part of holistic beauty and well-being routines, which are, in turn, driving the category’s projected growth. By 2028, the aesthetics market is predicted to nearly double in value, reaching $25.9 billion.1
NEXT by Galderma offers a future-forward perspective on the aesthetics industry. The report identifies six key emerging trends, bolstered by three core macro movements that are supporting industry growth. These six key trends have the potential to shape the aesthetics landscape and become mainstream in the future. The report takes an in-depth look at these trends from a neutral standpoint, as well as at the societal and cultural aspects underpinning the evolution of the aesthetics industry.
Commissioned by Galderma and based on research from a leading trend-forecasting authority, the report is informed by extensive data and analysis. NEXT by Galderma was co-developed by a network of almost 40 of the world’s leading healthcare professionals and esteemed beauty and skincare influencers.
“In partnership with a renowned trend-forecasting agency, and in collaboration with revered healthcare professionals and influencers, we’ve identified six trends poised to shape the future of aesthetics. The trends that we see emerging now have the potential to become bigger and impact consumer decisions regarding their beauty and skincare choices. At Galderma, everything we do in the world of aesthetics is a manifestation of our belief in “Aesthetic Possibilities, Shaped Together.” It’s a new, more collaborative and future-facing approach that is at the core of NEXT by Galderma.”
GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA
|
NEXT by Galderma: The six trends that are anticipated to shape consumer demand in aesthetics
- Proactive Beauty: Addressing aging before it is apparent has become paramount. The rise of “prejuvenation” treatments, which focus on prevention rather than cure, reflects today’s zeitgeist. For aesthetics, this means an increased shift toward early intervention.
- Mindful Aesthetics: The ethos of mindful beauty has reached the aesthetics market. Consumers are increasingly embracing products with minimal environmental impact that align with their ethical values and provide natural-looking results. Additionally, there is demand for products that seamlessly integrate with the body, indicating a push-back against artifice.
- Fast Aesthetics: That trends in fashion and cosmetics come and go is nothing new. But the addition of aesthetics treatments into the mix is a more recent—and noteworthy—development. More and more people now want to use aesthetics to mimic the latest fast-moving trends.
- Beauty Fandom: There is a new and more extreme take on fandom at play in the aesthetics world today. This trend indulges in fascination with niche idolization—from cultural icons to digital filters, anime, and beyond—which is leading to a desire for metamorphosis.
- Expressionality: There is greater interplay between a sense of self and self-expression. We live in an era that encourages individuality in fashion, styling, hair, makeup and, now, aesthetic treatments. This trend celebrates the empowerment that comes from creating and enhancing one’s identity with aesthetics.
- Cancelling Age: Beauty today is for every age, at any age. We are cancelling expectations of what certain ages “should look like,” as consumers employ aesthetics to express their ageless attitude. This trend shows how the evolving desire to not be defined by our age is increasing demand to preserve and enhance beauty, rather than solely reverse aging.
The six trends are underpinned by three macro movements:
- Increasing accessibility: More convenient, more affordable, more inclusive. The exponential rise of minimally invasive treatments, as well as increased access to treatments via new clinic locations and treatment options, are factors that have reshaped the beauty industry. The desire for inclusivity has had a major impact on the world of aesthetics at large.
- Advancements in science and technology: The rise of aesthetic tech, new product innovations and improvements on existing products have expanded not only the variety of treatment options available, but also their appeal.
- Social community: Social media has heightened consumer awareness and understanding around aesthetic treatments. Aesthetic practitioners are using social media to garner sizeable followings, highlighting that the world of aesthetics has a far-reaching platform of increasing influence.
As Galderma continues to navigate what lies ahead, driven by “Aesthetic Possibilities, Shaped Together,” there remains a firm focus on advancing dermatology for every skin story. The skin we’re in shapes our lives. That’s why Galderma’s unparalleled portfolio—along with our commitment to staying at the forefront of emerging technologies, medical education, thought leadership and training—is essential to shaping the future of aesthetics.
To view the abridged version of the NEXT by Galderma report, click here.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References:
- Markets and Markets (2022): Medical Aesthetics Market - Global Forecast to 2027. Hadapsar: Markets and Markets, pp. 1–257. Available at: https://www.marketsandmarkets.com/Market-Reports/medical-aesthetics-market-885.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206624555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
